Table 2 Treatment strategies according to the presence of heart failure
From: Characteristics of symptom burden in atrial fibrillation with concomitant heart failure
No. of patients n = 4885 | No HF | HF | p value |
|---|---|---|---|
n = 4322 | n = 563 | ||
Pharmacologic treatment | |||
ARB or ACEi | 1627 (37.7%) | 389 (69.5%) | < 0.001 |
Beta blocker | 2163 (50.1%) | 378 (67.5%) | < 0.001 |
Non-DHP CCB | 1322 (30.6%) | 136 (24.3%) | 0.002 |
Digoxin | 235 (5.4%) | 104 (18.6%) | < 0.001 |
Statin | 1501 (34.7%) | 241 (43.0%) | < 0.001 |
AF treatment strategy | < 0.001 | ||
Rhythm control | 2129 (49.3%) | 201 (35.7%) | |
Rate control only | 1564 (36.2%) | 317 (56.3%) | |
None | 629 (14.6%) | 45 (8.0%) | |
Non-pharmacological AF treatment | |||
Catheter ablation | 809 (18.7%) | 83 (14.8%) | 0.023 |
Electrical cardioversion | 748 (17.3%) | 131 (23.3%) | 0.001 |
Stroke prevention | |||
CHA2DS2-VASc ≤ 1 | 0.095* | ||
None | 797 (67.5%) | 20 (52.6%) | |
Anti-platelet agents | 22 (1.0%) | 0 (0.0%) | |
Oral anticoagulants | 362 (30.7%) | 18 (47.4%) | |
CHA2DS2-VASc ≥ 2 | 0.030* | ||
None | 550 (17.5%) | 72 (13.7%) | |
Anti-platelet agents | 13 (0.4%) | 0 (0.0%) | |
Oral anticoagulants | 2578 (82.1%) | 453 (86.3%) | |